Experimental retinopathy of prematurity: Angiostatic inhibition by nimodipine, ginkgo-biloba, and dipyridamole, and response to different growth factors

European Journal of Ophthalmology

Volumn 10, Issue 1, 2000, Pages 51-59

  Juarez C P ^a   Muino J C ^a   Guglielmone, H ^b   Sambuelli, R ^c   Echenique, J R ^a   Hernandez M ^a   Luna, J D ^a  

^a Fundacion VER   (Argentina)

^b LACE Laboratories   (Argentina)

^c UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

Author keywords

Angiogenesis; Dipyridamole; Ginkgo biloba; Neovascularization; Nimodipine

Indexed keywords

DIPYRIDAMOLE; GINKGO BILOBA EXTRACT; NIMODIPINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA BLOOD FLOW; RETROLENTAL FIBROPLASIA;

EID: 0034037313     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210001000109     Document Type: Article

References (41)

1. Prost ME. Problems of the pathogenesis of the retinopathy of prematurity. In: Reibaldi A, Di Prieto M, Scuderi A, Malerba E, eds. Progress in retinopathy of prematurity. Amsterdam, New york: Kugler Publications bv, 1997; 65-9.
2. Ashton N, Ward B, Serpell G. Effects of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954; 38: 397-402.
3. Pergamont Press, 1993; 12: 155-78.
4. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonists of integrin alpha-v beta-3 suppress retinal neovascularization in a murine model. Lab Invest 1996; 75: 563-73.
5. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Falkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long term dormancy of metastasis. J Clin Invest 1998; 101: 1055-63.
6. Dark GG, Hill SA, Prise VE, Tozer GM, Petit GR, Chaplin DJ. Combretastin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-34.
7. Petit GR, Rhodes MR. Antineoplastic agent 389. New synthesis of the Combretastin A-4 prodrug. Anticancer Drug Res 1998; 13: 183-91.
8. Campochiaro PA. Antiangiogenic drugs. In: Pathogenesis and treatment of age-related macular degeneration. Current knowledge and leads for future research. Baltimore: The John Hopkins University School of Medicine, USA. June 4-6, 1998.
9. Ernest JT, Goldstick TK. Retinal oxygen tension and oxygen reactivity in retinopathy of prematurity in kittens. Invest Ophthalmol Vis Sci 1984; 25: 1129-34.
10. Chang-Ling T, Gock B, Stone J. Supplemental oxygen therapy. Basis for non-invasive treatment of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 36: 1215-8.
11. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neo-vascularization in the newborn rat. Invest Opthalmol Vis Sci 1993; 34: 576-58.
12. Smith L, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-11.
13. Kuby J. Immunology. 3rd Ed. WH Freeman & Co. New York, Chapter 6: Antigen-Antibody Interactions 1997; 158-73.
14. De Jong ASH, van Kessel-van Vark M, Raap AK. Sensitivity of various visualization methods for peroxidase and alkaline phosphatase activity in immunoenzyme histochemistry. Histochem J 1985; 17: 1119-30.
15. Nieto A, Carbonetto Ch. Enzimoinmunoensayo (ELISA). En: Margni ed. Inmunologia e Inmunoquimica. 4ta Edición. Panamericana, Buenos Aires, 1989; 571-86.
16. Luna JD, Muiño JC, Hernández M, Juárez CP. Effects of Ginkgo-biloba extract in a premature piglet model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1992; 33 (suppl): S1086.
17. Jampol MI, Ebroon DA, Gouldbaum MH. Peripheral proliferative retinopathies: An update in angiogenesis, etiologies and management. Surv Ophthalmol 1994; 38: 519-28.
18. Aiello LP. Vascular endothelial growth factor and the eye. Past, present and future. (Editorial). Arch Ophthalmol 1996, 114: 1252-53.
19. Díaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol 1994; 9: 807-16.
20. Muiño JC. Asthma and specific inhibitor of PAF. ACT News 1990; 2: 75-7.
21. Bazán HEP, Tao Y, Hurst JS. Platelet-activating factor antagonist and ocular inflammation. J Ocular Pharmacol 1994; 10: 319-27.
22. Schulam PG, Kuruvilla A, Putcha G, Mangus L, Franklin Johnson J, Shearer WT. Platelet-activating factor induces phospholipid turnover, calcium flux, arachidonic acid liberation, eicosanoid generation, and oncogene expression in a human B cell line. J Immunol 1991; 146: 1642-8.
23. Suga K, Kawasaki T, Blank ML, Snyder F. An arachidonic (polynoic)-specific phospholipase A2 activity regulates the synthesis of platelet-activating factor in granulocytic HL-60 cells. J Biol Chem 1990; 265: 12363-7.
24. Bazán HEP, Tao Y, DeCoster MA, Bazán NG. Platelet-activating factor induces cyclooxygenase-2 gene expression in corneal epithelium. Requirement of calcium in the signal transduction pathway. Invest Ophthalmol Vis Sci 1997; 38: 2492-501.
25. Braquet P, Spinnwyn B, Braquet M. BN 52021 and related compounds. A new class of highly specific PAF-acether receptor antagonist isolated from Ginkgo-biloba. Blood Vessels 1985; 16: 559-72.
26. Bussolino D, Gremo F, Tetta C, Pescarmmona GP, Carmussi G. Production of platelet-activating factor by cesik retina. J Biol Chem 1986; 261: 16502-8.
27. Mori M, Aihara M, Shimizu T. Localization of platelet-activating factor receptor messenger RNA in the rat eye. Invest Ophthalmol Vis Sci 1997; 38: 2672-8.
28. Barron KD. The microglial cell. A historical review. J Neurol Sci 1995; 134 (suppl): S57-68. Review.
29. Smith D, Lee ER, Saloupis P, Davis JK, Hatchell DR. Role of neutrophils in breakdown of blood-retinal barrier following intravitreal injection of platelet-activating factor. Exp Eye Res 1994; 59: 425-32.
30. Harris A, Evans DW, Cantor LB, Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am J Ophthalmol 1997; 124: 296-302.
31. Bose S, Piltz J, Breton M. Nimopidine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects. Ophthalmology 1995; 102: 1236-41.
32. Netland PA, Erickson KA. Calcium channel blockers in glaucoma management. Ophthalmol Clin North Am 1995; 8: 327-34.
33. Leidig S, Michelson G. Influence of the calcium antagonist nimodipine on the vasoconstrictive effect of breathing 100% oxygen on retinal blood flow. Invest Ophthalmol Vis Sci 1998; 39 (suppl): S272.
34. Michelson G, Leidig S, Mück W, Geisslinger G. Calcium antagonist blood-concentration and effects on retinal blood flow in normals. Invest Ophthalmol Vis Sci 1998; 39 (suppl): S273.
35. Kristinsson JK, Harris A, Chang HS, Ciulla TA, Ritch R. Ginkgo-biloba extract increases ocular blood flow velocity. Invest Ophthalmol Vis Sci 1998; 39 (suppl): S476.
36. Kruger A, Matulla B, Wolzt M, et al. Short term oral pentoxifylline use increases choroidal blood flow in patients with age-related macular degeneration. Arch Ophthamol 1998; 116: 27-30.
37. Meyer P, Flammers J, Luscher TF. Effect of dipyridamole on vascular responses of porcine ciliary arteries. Curr Eye Res 1996; 15: 387-93.
38. Campochiaro PA, Sen HA. Adonosine and its antagonists cause retinal vasodilation and hemorrhages. Implications for ischemic retinopathies. Arch Ophthalmol 1989; 107: 412-6.
39. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993; 193: 631.
40. Aiello L, Northrup J, Keyt B, Takagi H, Iwamoto M. Hypoxy regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-42.
41. Khon EC, Alessandro R, Sfonsler J, Wersto RP, Liotta LA. Angiogeresis: role of calcium-mediated signal transduction. Proc Natl Acad Sci 1995; 92: 1307-11.